Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GSK1070806 for Prevention of Delayed Graft Function in Renal Transplantation
NCT02723786Phase 2Terminated
- Sponsor
- GSK
- Start
- Aug 2016
- Primary completion
- Mar 2017
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of aletekitug in delayed graft function (DGF), sponsored by GSK. Started Aug 2016; status: terminated.
02
Drugs
aletekitug
03
Conditions
delayed graft function (DGF)
Beyond the preview
Go deeper on NCT02723786.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02723786.